May 30 Resverlogix Corp
* Resverlogix receives approval from health canada to proceed with fabry disease clinical trial with lead compound apabetalone
* Resverlogix- received approval from health canada, therapeutic products directorate, to proceed with clinical trial with lead compound apabetalone in patients with fabry disease Source text for Eikon: Further company coverage:
WORLD NEWS SCHEDULE AT 1800 GMT/2 PM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts
CEO of Raytheon's Forcepoint eyes IPO -Boersen-Zeitung
FRANKFURT, June 24 U.S. missile maker Raytheon's cybersecurity unit could thrive were it to be listed separately, the head of the unit, Forcepoint, told German business daily Boersenzeitung in an interview published on Saturday.